USO DEL CANNABIDIOL COMO ALTERNATIVA EN EL TRATAMIENTO DE LA DERMATITIS ATOPICA Y PSORIASIS
DOI:
https://doi.org/10.47820/recima21.v4i11.4313Palabras clave:
Cannbis, cannabidiol, dermatitis, psoriasis, tratamientoResumen
La dermatitis atópica y la psoriasis son enfermedades inflamatorias crónicas de la piel con manifestaciones características. La dermatitis atópica, asociada a la predisposición genética, presenta eccema debido a una tríada de causas: desregulación inmunitaria, alteración del microbioma cutáneo y disfunción de la barrera cutánea. Hay teorías que debaten la secuencia de estas causas, algunas afirman que la disfunción de la barrera desencadena la respuesta inmunitaria y otras creen lo contrario. La psoriasis se caracteriza por la aparición de lesiones papuloescamosas y puede asociarse a artritis psoriásica. Su fisiopatología está relacionada con desequilibrios en el sistema inmunológico, particularmente involucrando a las células CD4+, Th1 y Th17. Una planta, el Cannabis sativa, ha ganado protagonismo en el tratamiento de estas afecciones debido a la presencia de cannabinoides, especialmente CBD. El sistema endocannabinoide, presente en el cuerpo humano, interactúa con estos cannabinoides, proporcionando efectos antiinflamatorios y antioxidantes, que son beneficiosos para el tratamiento de la dermatitis atópica y la psoriasis. Los estudios apuntan a la eficacia de los cannabinoides en la inhibición de la proliferación de queratinocitos y la modulación de los componentes inflamatorios. Sin embargo, aún se necesita más investigación para estandarizar las dosis y las formulaciones, así como para determinar la seguridad y eficacia del uso del cannabis medicinal en afecciones dermatológicas.
Descargas
Citas
DOMANSKY, C.R; BORGES, L.E. Manual para prevenção de lesões de pele. Recomendações baseadas em evidências. Rio de Janeiro: Editora Rubio,2012.
ANTUNES AA, et al. Guia prático de atualização em dermatite atópica - Parte I: etiopatogenia, clínica e diagnóstico. Arquivos de Asma, Alergia e Imunologia, 2017; 1(2): 131-56.
CZARNOWICKI T, et al. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol, 2019 Jan; 143(1): 1-11
BASLER K, et al. The role of tight junctions in skin barrier function and dermal absorption. J Control Release, 2016 Nov 28; 242: 105-118.
Belsito DV. The diagnostic evaluation, treatment, and prevention of allergic contact dermatitis in the new millennium. J Allergy Clin Immunol. 2000; 105:409-20.
WEIDINGER S, NOVAK N. Atopic dermatitis. Lancet, 2016; 387(10023): 1109-1122.
. DARLENSKI R, et al. Atopic dermatitis as a systemic disease. Clin Dermatol, 2014 May-Jun; 32(3): 409-13
Soutor C, Hordinsky M. Dermatologia clínica. Porto Alegre: Grupo A; 2014.
Rendon, A., & Schäkel, K. (2019). Psoriasis Pathogenesis and Treatment. International journal of molecular sciences, 20(6), 1475. https://doi.org/10.3390/ijms20061475
Kumar, V., Abbas, A., & Aster, J. (2016). Robbins & Cotran Patologia - Bases Patológicas das Doenças (9th edição). Grupo GEN. https://integrada.minhabiblioteca.com.br/books/9788595150966
Krueger, J. G., & Bowcock, A. (2005). Psoriasis pathophysiology: Current concepts of pathogenesis. Annals of the Rheumatic Diseases, 64(SUPPL. 2), 30–36. https://doi.org/10.1136/ard.2004.031120
11. Azulay, R. D. (2017). Dermatologia, (7ª edição.) Grupo GEN. https://integrada.minhabiblioteca.com.br/books/9788527732475
HAJAR T, et al. New and developing therapies for atopic dermatitis. An Bras Dermatol, 2018; 93(1): 104-107
CARVALHO VO, et al. Guia prático de atualização em dermatite atópica - Parte II: abordagem terapêutica. Arquivos de Asma, Alergia e Imunologia, 2017; 1(2): 157-82.
Association NE. Can cannabis help your eczema? What you need to know. [Internet]. National Eczema Association. 2017. Available from: https://nationaleczema.org/blog/can-marijuana-help/
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC pediatrics. 2016;16:75.
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116-32
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606
Sheriff, T., Lin, M. J., Dubin, D., & Khorasani, H. (2019). The potential role of cannabinoids in dermatology. J. Dermatolog Treat, 31 (8), 839-845.https://pubmed.ncbi.nlm.nih.gov/31599175/#:~:text=Cannabinoids%20have%20demonstrated%20anti%2Dinflammatory,promising%20alternative%20to%20traditional%20treatments
Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences [Internet]. 2009 Aug;30(8):411–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757311/
Jarząb S. Cannabidiol – characteristic and application in cosmetology and dermatology [Internet]. Aesthetic Cosmetology. 2021 [cited 2023 Jun 17]. Available from: https://aestheticcosmetology.com/cannabidiol-characteristic-and-application-in- cosmetology-and-dermatology/
Grupta, A. K., & Talukder, M. (2021). Cannabinoids for skin diseases and hairre growth. Wiley Online Library, 20 (9), 2703-2711.https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.14352#:~:text=Skin%20disorders%20and%20hair%20growth,hair%20growth%20via%20multiple%20mechanisms
Cristino L, Bisogno T, Di Marzo V. Cannabinoid and the expanded endocannabinoid system in neurological disorders Nature Reviews Neurology [Internet]. 12 de janeiro de 2020 [citado 4 de fevereiro de 2020];16(1):9–29. Available at: http://www.nature.com/articles/s41582-019-0284-z
Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clinical, Cosmetic and Investigational Dermatology [Internet]. 2020; 13:927–42. Available from: https://pubmed.ncbi.nlm.nih.gov/33335413/
Viana LS, Aires Silva T, Antunes VM de S, Gonzaga RV. Efeito do óleo de Canabidiol (CBD) sobre a acne. Research, Society and Development. 2021 Nov 2;10(14): e306101422075.
Lee SF, Newton C, Widen R, Friedman H, Klein TW. Differential expression of cannabinoid CB2 receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur J Pharmacol. 2001;423(2-3):235-41.
Howlett AC. Cannabinoid receptor signaling. Handb Exp Pharmacol. 2005; 168:53- 79.
Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective Properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem. 2002;80(3):448-56.
MARZO, Bisogno T, De Petrocellis L. Endocannabinoids: new targets for drug development. Curr Pharm Des. 2000 Sep;6(13):1361-80. doi: 10.2174/1381612003399365. PMID: 10903398.
MOREIRA, E. M. F., & de Sousa, M. N. A. (2021). USO TERAPÊUTICO DA CANNABIS SATIVA PARA O TRATAMENTO DE DOENÇAS. Journal of Medicine and Health Promotion, 6(1), 292-301.)
LUCENA, João Gabriel Almeida de. Canabinóides: do uso abusivo à aplicação terapêutica. Araraquara 77 f , 2021.
Coimbra BZ, Bertozzi JG, Borges ED, Pitliuk R, Fucci TPP da CS, Abreu MAMM de. Canabinóides como possível alternativa no tratamento de psoríase. Research, Society and Development [Internet]. 2022 Sep 18 [cited 2023 May 4];11(11): e450111134651–e450111134651. Available from: https://rsdjournal.org/index.php/rsd/article/view/34651
SCHIER , Alexandre Rafael de Mello et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Brazilian Journal of Psychiatry [online]. 2012, v. 34, suppl one [Acessado 20 Junho 2022], pp. 104-110. Disponível em: <https://doi.org/10.1590/S1516-44462012000500008>. Epub 19 Jun 2012. ISSN 1809-452X. https://doi.org/10.1590/S1516-44462012000500008.
ELSAID, Sonja; KLOIBER, Stefan; LE FOLL, Bernard. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. In: PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE. [S. l.]: Elsevier, 2019. v. 167, p. 25–75. Disponível em: https://doi.org/10.1016/bs.pmbts.2019.06.005. Acesso em: 24 mar. 2020.
Scheau, C., Badarau, I. A., Mihai, L. G., Scheau, A. E., Costache, D. O., Constantin, C., Calina, D., Caruntu, C., Costache, R. S., & Caruntu, A. (2020). Cannabinoids in the Pathophysiology of Skin Inflammation. Molecules (Basel, Switzerland), 25(3), 652. https://doi.org/10.3390/molecules25030652
Friedman, A. J., Momeni, K., & Kogan, M. (2020). Topical Cannabinoids for the Management of Psoriasis Vulgaris: Report of a Case and Review of the Literature.Journal of drugs in dermatology: JDD,19(8), 795. https://doi.org/10.36849/JDD.2020.5229
Ramot, Y., Sugawara, K., Zákány, N., Tóth, B. I., Bíró, T., & Paus, R. (2013). A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ. PeerJ, 1, e40. https://doi.org/10.7717/peerj.40
Norooznezhad, A. H., & Norooznezhad, F. (2017). Cannabinoids: Agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Medical hypotheses, 99, 15–18. https://doi.org/10.1016/j.mehy.2016.12.003
Shao, K., Stewart, C., & Grant-Kels, J. M. (2021). Cannabis and the skin. Clinics in dermatology, 39(5), 784–795. https://doi.org/10.1016/j.clindermatol.2021.05.006
Lima, E. de A., & Lima, M. de A. (2011). Imunopatogênese da psoríase: revisando conceitos. Anais Brasileiros de Dermatologia, 86(6), 1151–1158. https://doi.org/10.1590/s0365-05962011000600014
Milano, R., & Friedman, A. (2019). Cannabinoids: potecial ole in inflammatory and neoplastic skin diseases. Am J Clin Dermatol, 20 (2), 167-180.https://pubmed.ncbi.nlm.nih.gov/30542832
Descargas
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
